The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, pharma industry deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for professionals who need to stay ahead. Hosts voices are AI created.

The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes is a science podcast hosted by Unknown Host, with 147 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes, a science show with 147 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes

  Week in Review | AstraZeneca’s Setback, Novartis Under Pressure & Scholar Rock’s Approval

  Sep 13, 202614 min

  AstraZeneca's broader-use trial of Etcamah (camizestrant)missed its primary goal in advanced breast cancer, while the existing approval stands. Scholar Rock's ISEMBYLD (apitegromab) adds a muscle-directed option inspinal muscular atrophy, while Roivant's mosliciguat links vascular improvement with better walking distance in pulmonary hypertension associated with interstitial lung disease. Novartis faces pipeline and acquisition scrutiny asBiohaven pauses new BHV-7000 enrollment and Karyopharm confronts near-term financing pressure. Encoded's ETX101 results frame its Dravet syndromefinancing, and BioNTech's lung-cancer presentations lead the week ahead. Alex Mercer and Maya Patel host. Get the daily rundown inyour inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  Episode #171

  Exelixis Faces FDA Delay & Karyopharm Faces October Deadline

  Sep 12, 20269 minS1

  FDA extended its review of Exelixis's zanzalintinib-Tecentriq combination for metastatic colorectal cancer to March 3, 2027, after classifying updated data as a major amendment. Karyopharm missed a $15.8 million loan payment and secured a creditor standstill through October 15 tied partly to its selinexor-ruxolitinib myelofibrosis filing. Roche's Enspryng gained Priority Review in MOGAD; COSCIENS bought oral-film manufacturer Nualtis, and Frazier raised more than $1.1 billion for its Public Fund. Plus, Telix's Pixclara FDA decision remained unverified at our reporting cutoff. Alex Mercer and Maya Patel host the Daily Roundup for September 11. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  Episode #170

  Biohaven Faces FDA Enrollment Hold & AbbVie Reports Menstrual Migraine Results

  Sep 11, 20269 minS1

  Biohaven's FDA partial hold pauses new epilepsy-trialenrollment; the company still expects RISE-3 results this year. AbbVie reports LUNA menstrual-migraine results for oral Qulipta (atogepant), while Shionogi misses a stroke endpoint and Disc Medicine reports fewer blood-removalprocedures in early polycythemia vera data. Novartis faces shareholder pressure, Solstice raises $225 million, and MannKind partners with Rose Pharma on inhaled weight management. NICE questions the value of Gilead's lenacapavir for HIV prevention, and new consensus guidance addresses type 1 diabetes screening. Alex Mercer and Maya Patel host the Daily Roundup forSeptember 10. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.

  ListenShow Notes
• 

  Episode #169

  Bayer's Hyrnuo Enters First-Line Rivalry & FDA Gets Permanent Center Chiefs

  Sep 10, 202612 minS1

  Bayer's Hyrnuo (sevabertinib) gains first-line accelerated approval in HER2-mutant lung cancer, joining an established rival. Permanent FDA center leaders follow repeated turnover, while Structure's experimental obesity pill aleniglipron adds 72-week follow-up without a concurrent placebo. Kura, EMD Serono and Encoded back new development efforts; Tyra reports early bladder cancer responses, Evommune changes its eczema program, and Beeline advances lupus studies. BioMarin's Voxzogo (vosoritide) filing targets hypochondroplasia, and Nanoscope reports application acceptance for severe retinitis pigmentosa. Alex Mercer and Maya Patel host the Daily Roundup for September 9. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com .

  ListenShow Notes
• 

  Episode #168

  Novartis's HARBOR Miss Tests Confidence in the Growth Plan & Rasonque's Access Hurdles

  Sep 8, 202610 minS1

  Novartis's del-desiran missed HARBOR's primary endpoint in myotonic dystrophy, adding pressure to a growth plan already facing setbacks. Roivant and Pulmovant's mosliciguat data advance Monday's PHocus preview, while AstraZeneca, Pharvaris, Amgen, Inhibrx and Bristol Myers add clinical updates across lung disease, hereditary angioedema and cancer. BrainChild Bio's financing, the proposed Sernova-Seraxis merger and Intellia's lonvo-z Priority Review round out the slate. Two resolved Rasonque access cases show why Revolution Medicines' pancreatic cancer launch requires more than approval: patients still need to navigate authorization, support and dispensing. Alex Mercer and Maya Patel host the Daily Roundup for September 8. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com .

  ListenShow Notes

Recent guests on The Pharma Closeout | Daily Pharmaceutical & Biotech News in 15 Minutes. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.